Clinical Study
A Nonimmunosuppressant Approach on Asia Psoriasis Subjects: 5-Year Followup and 11-Year Data Analysis
Table 3
Immunosuppressants modalities in China and Singapore patients with psoriasis.
| | Immunosuppressants modalities in China and Singapore patients with psoriasis | % |
| | Topical | | | Corticosteroids | 98.7% | | Calcipotriol | 30.2% | | Retinoid | 11.4% | | Tacrolimus | 3.8% | | Systemic | | | Systemic glucocorticoid | 46.6% | | UVB or PUVA | 21.5% | | Methotrexate | 15.7% | | Cyclosporine | 5.2% | | Azathioprine | 0.2% | | Hydroxyurea | 0.2% | | Herbal decoction | | | Glycyrrhiza (Gan Cao), Licorice [13–15] | 71.5% | | Lonicera (Jin Yin Hua), Honeysuckle | 71.5% | | Dictamnus (Bai Xian Pi), Burning Bush [16] | 71.5% | | Cryptotympana (Chan Tui), Cicada Slough | 71.5% | | Tripterygium (Lei Gong Teng), Threewingnut [17–20] | 14.5% | | Sophora (Ku Shen), Flavescent Sophora [15, 21, 22] | 62.4% | | Prunella (Xia Ku Cao), Self Heal [23] | 71.5% | | Curcuma (Jiang Huang, Yu Jin), Turmeric [24–27] | 71.5% | | Bupleurum (Chai Hu), Thorowax [28–30] | 23.0% | | Cordyceps sinensis (Dong Chong Xia Cao) [31, 32] | 35.4% |
|
|
